Sumitomo Mitsui Trust Group Inc. boosted its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 13.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,800,461 shares of the company's stock after acquiring an additional 583,887 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.25% of Kenvue worth $111,035,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of KVUE. Leo Wealth LLC boosted its stake in Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company's stock worth $3,507,000 after acquiring an additional 481 shares in the last quarter. Massmutual Trust Co. FSB ADV boosted its holdings in Kenvue by 6.2% in the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company's stock worth $194,000 after acquiring an additional 492 shares in the last quarter. Wolff Wiese Magana LLC grew its stake in Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company's stock valued at $1,781,000 after acquiring an additional 501 shares during the period. Marathon Capital Management increased its holdings in shares of Kenvue by 0.3% during the second quarter. Marathon Capital Management now owns 149,699 shares of the company's stock valued at $2,722,000 after acquiring an additional 514 shares in the last quarter. Finally, Poehling Capital Management INC. raised its position in shares of Kenvue by 0.5% during the second quarter. Poehling Capital Management INC. now owns 104,934 shares of the company's stock worth $1,908,000 after purchasing an additional 547 shares during the period. 97.64% of the stock is owned by institutional investors.
Kenvue Stock Performance
Kenvue stock traded up $0.52 during mid-day trading on Thursday, reaching $23.66. The company's stock had a trading volume of 6,184,847 shares, compared to its average volume of 18,027,182. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $45.36 billion, a P/E ratio of 42.62, a PEG ratio of 2.15 and a beta of 1.36. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $23.95. The firm's fifty day moving average price is $22.73 and its two-hundred day moving average price is $20.63.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to analysts' expectations of $3.92 billion. During the same quarter in the prior year, the firm posted $0.31 earnings per share. The business's quarterly revenue was down .4% on a year-over-year basis. Sell-side analysts predict that Kenvue Inc. will post 1.07 EPS for the current fiscal year.
Kenvue Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.47%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue's dividend payout ratio (DPR) is currently 149.09%.
Analyst Upgrades and Downgrades
A number of brokerages have commented on KVUE. Jefferies Financial Group initiated coverage on shares of Kenvue in a research note on Tuesday, September 24th. They set a "buy" rating and a $27.00 price target for the company. UBS Group lifted their price target on Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Wednesday, August 7th. Bank of America increased their price objective on Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft lifted their target price on Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. Finally, Piper Sandler raised their price objective on Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $22.64.
Get Our Latest Stock Analysis on Kenvue
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
